Search

Issue
Title
Authors
How a significant increase in survival in pancreatic cancer is achieved. The role of nutritional status and supportive care: A review
Zhukova L.G., Bordin D.S., Dubtsova E.A., Ilin M.A., Kiriukova M.A., Feoktistova P.S., Egorov V.I.
Relationship of the integrin profile of the primary tumor to metastasis to regional lymph nodes in breast cancer
Zavyalova M.V., Kuznecov G.A., Grigoryeva E.S., Tashireva L.A., Pismenny D.S., Perelmuter V.M.
Remote multimodal prehabilitation in the presence of cachexia and resectable gastric cancer: a clinical case
Lyadov V.K., Boldyreva T.S., Achkasov E.E., Gorshkov A.Y., Chashchin M.G., Protsenko E.V., Starodubova V.V., Galkin V.N.
Rare histological subtypes of bladder cancer in clinical practice: a case series
Paychadze A.A., Golubeva S.A., Kamalova M.A.
Updates in urologic oncology guidelines: prostate cancer: A review
Volkova M.I., Alekseev B.Y., Nosov D.A., Nyushko K.M.
The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study
Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Stilidi I.S., Tupitsyn N.N.
The effect of antioxidant drugs on the self-assessment of clinical symptoms in women during radiation therapy after surgical treatment of endometrial cancer: Placebo-controlled randomized trial
Volchegorskii I.A., Vazhenin A.V., Alekseeva A.P.
Assessment of the impact of the use of durvalumab for the treatment of advanced small cell lung cancer on the achievement of the target "reduction in mortality from neoplasms"
Ryazhenov V.V., Orlov S.V., Ivakhnenko O.I.
Immuno-morphological characteristics of bone marrow in patients with ovarian cancer
Kozhonalieva A.M., Chulkova S.V., Stilidi I.S., Artamonova E.V., Poddubnaya I.V., Kolbatskaya O.P., Kupryshina N.A., Egorova A.V., Tupitsyn N.N.
Gastric cancer: Russian clinical guidelines
Besova N.S., Kalinin A.E., Nered S.N., Triakin A.A., Gamaiunov S.V., Kozlov N.A., Stilidi I.S., Karachun A.M., Kononets P.V., Malikhova O.A., Riabov A.B., Khomiakov V.M., Fedenko A.A., Bolotina L.V., Falaleeva N.A., Nevol'skikh A.A., Ivanov S.A., Khailova Z.V., Gevorkian T.G., Butenko A.V., Gil'mutdinova I.R., Eremushkin M.A., Ivanova G.E., Kondrat'eva K.O., Konchugova T.V., Krutov A.A., Obukhova O.A., Semiglazova T.I., Filonenko E.V., Khulamkhanova M.M., Romanov A.I.
Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
Sekacheva M.I., Fatyanova A.S., Meretukov D.A., Zhilenkova A.V., Rusanov A.S., Rozhkov A.A., Guryanova A.A., Bagmet N.N.
Antiangiogenic therapy for breast cancer with triple negative phenotype
Ganshina I.P., Ivanova K.A., Gordeeva O.O., Arkhipov A.V., Zhukova L.G.
Can any breast skin thickening be staged as T4?
Amosova V.A., Petrovskii A.V., Karpova M.S., Ponedel’nikova N.V., Frolova M.A.
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Mazurina N.V., Artamonova E.V., Beloyartseva M.F., Volkova E.I., Ganshina I.P., Troshina E.A., Tjulandin S.A., Chubenko V.A.
Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
Kononenko I.B., Snegovoy A.V., Grebennikova O.P., Sel’chuk V.Y., Palchinskaia O.V.
Virus-associated pharynx tumors in a 16-year-old boy: the description of the clinical case
Gorbunova T.V., Radtsig E.I., Merkulov O.A., Bogomil’skii M.R., Poliakov V.G.
The use of regorafenib in colorectal cancer
Sekacheva M.I., Bagmet N.N., Guryanova A.A., Rashi D.A.
The effectiveness of targeted therapy in the treatment of common forms of ovarian cancer
Saevets V.V., Vazhenin A.V., Chernova L.F., Shimotkina I.G., Kurchenkova O.V., Mukhin A.A., Taratonov A.V.
Ramucirumab therapy in patients with advanced gastric cancer: discussion of a case series
Orlova R.V., Zhukova L.G., Ganshina I.P., Yukalchuk D.Y., Ponomarenko D.M., Beliak N.P., Gordeeva O.O., Erdniev S.P., Minasyan A.A., Dashkova A.A., Sopiya E.R., Sholokhova E.A., Gurochkin A.B.
Clinico-morphological predictors and treatment outcomes in cervical stump cancer
Usmanova L.S., Kuznetsov V.V., Mustafina E.A., Barinov V.V., Bokin I.I., Knyazev R.I., Akhmedova M.D.
Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
Sekacheva M.I., Bagmet N.N.
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
Choice of anti-angiogenic agents in second-line treatment in patients with metastatic colon cancer: bevacizumab, aflibercept, ramucirumab (a literature review)
Fedyanin M.I.
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A.
Male breast cancer: review of the literature
Nikolaev K.S., Semiglazov V.F., Semiglazov V.V.
Radiological diagnostics of colorectal cancer liver metastases and immunohistochemical characteristics after drug treatment
Skipenko T.O., Paltseva E.M., Sekacheva M.I., Bedganian A.L.
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
Clinical example of the drug pazopanib as a targeted therapy in inoperable cancer of the kidney
Klimenko A.A., Ivanov S.A.
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A.
Diagram of differential diagnostics of stages of ovarian cancer
Antoneeva I.I., Abakumova T.V., Gening T.P., Gening S.O.
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K.S., Sukhova M.V., Kolyago E.M., Filonenko D.A., Zhukova L.G.
The first experience in Russia of applying a tumor differentiation protocol in a patient with progressive, radioiodine-refractory BRAF-positive papillary thyroid cancer. Case report
Slashchuk K.Y., Reinberg M.V., Serzhenko S.S., Sheremeta M.S., Nikiforovich P.A.
Predictive modeling of the probability of gynecological complications of tamoxifen therapy: A prospective study
Golubenko E.O., Savelyeva M.I., Korennaya V.V., Podzolkova N.M., Valiev T.T.
What type of intervention works best to help people with cancer get back to work?(Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)
Editorial B.
Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study
Volkova M.I., Kalpinskiy A.S., Goncharova O.A., Menshikov K.V., Karabina E.V., Dergunov A.S., Polshina N.I., Alexandrova E.N., Lebedinets A.A., Panov A.К., Sultanbaev A.V., Usynin E.A., Volkonskiy M.V., Mikhalyuk V.V., Zukov R.A., Anzhiganova Y.V., Gusniev M.A., Igumnova E.N., Kuzmicheva S.V., Pokataev I.A., Olshanskaya A.S., Pervakova N.I., Parsadanova E.L., Sannikova T.A., Bystrov A.A., Dubovichenko D.M., Miliausha M.R., Chubenko V.A., Shkret K.A., Gorshenina M.N., Davlatova M.К., Kosareva A.E., Lutoshkina O.A., Maslova O.A., Makhnutina M.V., Mishina A.V., Murzalina M.Z., Podyacheva O.A., Kalinin S.A., Mailyan O.A., Safarova A.R., Semenova K.O., Strokova M.A., Urashkina E.Y., Shmygina O.S.
Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
Ognerubov N.A.
Opportunities of ICG-fluorescent imaging of lymph nodes during radical cystectomy in patients with bladder cancer: A review
Pavlov V.N., Urmantsev M.F., Bakeev M.R.
Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study
Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Stilidi I.S., Burov D.A., Tupitsyn N.N.
Current concepts of neuroendocrine cancer of the prostate: a clinical case and review of the literature
Chizh G.A., Tyutrina Y.A., Protsenko S.A., Dzhelialov E.S., Latipova D.H.
Recurrent of ovarian cancer with lymph node involvement: surgery or chemotherapy? Retrospective cohort study
Stilidi I.S., Egenov O.A., Nered S.N., Kalinin O.E., Shevchuk A.S., Arkhiri P.P., Suleymanov E.A., Tyulyandina А.S.
Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence
Editorial B.
The era of immuno-oncology in onco-urology: what have we achieved? The review of the symposium of the alliance between Merck and Pfizer held within the framework of the XXV Russian Oncology Congress. November 9, 2021
Editorial B.
Laparoscopic resections of the liver and the colon in patients with synchronous colorectal metastases: a case series
Lyadov V.K., Moskalenko A.N., Britskaia N.N.
Regorafenib in metastatic colorectal cancer: more data for clinical decisions
Petkau V.V., Karimova A.A., Akishina Z.V.
Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
Zhabina A.S., Moiseenko F.V., Volkov N.M., Abduloeva N.K., Moiseenko V.M.
Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
Samaneva N.I., Vladimirova L.I., Kolyadina I.V., Frantsiyants E.M., Storozhakova A.E., Bandovkina V.A., Kalabanova E.A., Kabanov S.N., Svetitskaya I.V., Tishina A.V., Ezhova M.O.
Squamous cell breast cancer: description of a rare clinical case
Zikiryakhodjaev A.D., Khakimova S.G., Rasskazova E.A., Saribekian E.K., Omarova D.F., Surkova V.S., Khakimova G.G.
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
Poddubnaya I.V., Gligorov J., Zhukova L.G., Kovalenko E.I., Frolova M.A.
Meta-analysis of the studies dedicated to the predictive significance of circulating tumor DNA in pancreatic cancer
Popova A.S., Fedyanin M.Y., Pokataev I.A., Tyulyandin S.A.
Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
Statsenko G.B., Kurakin V.I., Plokhotenko I.V.
Durvalumab in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy in a real practice
Sakaeva D.D., Ruchkin V.V., Goncharova O.V., Abbasova R.R., Mufazalov F.F.
Differential diagnosis of lung cancer and tuberculosis: review
Belova O.S., Komarov I.G.
Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients
Artamonova E.V., Kovalenko E.I., Snegovoy A.V., Aksarin A.A., Anciferova T.A., Belonogov A.V., Bilan E.V., Bilenko S.N., Varvus I.M., Gorkovenko E.A., Enikeev R.F., Ermolaeva A.M., Kramskaya L.V., Kononenko I.B., Pechenyy A.P., Safina S.Z., Chupriyanova T.V., Chuhua G.G., Shemyakina A.I., Shikina E.V.
Ribociclib in 1st line HR+ breast cancer treatment
Zhukova L.G., Ganshina I.P., Gordeeva O.O., Lubennikova E.V.
Clinical cases of the treatment of metastatic colorectal cancer in Russia
Goldberg V.E., Hasanova A.I., Shkuratova V.V., Belevich Y.V., Popova N.O., Simolina E.I., Vysockaya V.V., Dudnikova E.A., Kravchuk T.L., Minnabetdinova R.R., Nekrasova O.V.
Brachytherapy with ultrasound assistance in patients with cervical cancer
Kizhaev Y.E., Razumova E.L., Bessolova O.V.
The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
Ryazhenov V.V.
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
Nenahova Y.N., Lyadov V.K., Poddubnaya I.V.
Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
Vladimirova L.Y.
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
BRCA-associated ovarian cancer (the experience of the Chemotherapy Department in N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of Russia)
Khokhlova S.V., Gorbunova V.A., Lyubchenko L.N., Imyanitov E.N.
Clinical and prognostic significance of matrix metalloproteinase-7 and vascular endothelium growth factor in patients with ovarian cancer
Knyazev R.I., Poddubnaya I.V., Bokin I.I., Barinov V.V.
Stereotactic biopsy of breast lesions under x-ray control
Manikhas G.M., Safronova O.B., Khudjakova T.G., Barabanova L.P., Punanova N.J.
Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
Gridneva Y.V., Matveev V.B., Kupchan D.Z., Kalinin S.A., Peters M.V.
Pharmacoeconomic usefulness of the drug Giotrif® (afatinib) in first-line treatment of locally advanced or metastatic non-small cell lung cancer with a mutation of epidermal growth factor receptor (EGFR)
Kolbin A.S., Kurylev A.A., Pavlysh A.V., Proskurin M.A., Balykina Y.Y.
HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
Besova N.S.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A., Koroleva N.I.
Selection of the anti-angiogenesis therapy for the first-line chemotherapy in advanced ovarian cancer
Khokhlova S.V.
VEGF inhibitors: a new era in the treatment of metastatic ovarian cancer
Pignata S.
301 - 369 of 369 Items << < 1 2 3 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».